肝炎、肝がんを中心とした病態解明と新規診断・治療法の開発

1. Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T.
   Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol. 2019 Apr 2. doi: 10.1007/s00535-019-01579-5. (Epub ahead of print)
   
   
   
2. Doi H, Yoshio S, Yoneyama K, Kawai H, Sakamoto Y, Shimagaki T, Aoki Y, Osawa Y, Yoshida H, and Kanto T.
   Immune Determinants in the Acquisition and Maintenance of Anti-HBs in Adults After First-Time Hepatitis B Vaccination Hepatol Commun. 2019 Apr 22;3(6):812-824. doi: 10.1002/hep4.1357. eCollection 2019 Jun.
   
   
   
3. Tomonari Shimagaki, Sachiyo Yoshio, Hironari Kawai, Yuzuru Sakamoto, Hiroyoshi Doi, Michitaka Matsuda, Taizo Mori, Yosuke Osawa, Moto Fukai, Takeshi Yoshida, Yunfei Ma, Tomoyuki Akita, Junko Tanaka, Akinobu Taketomi, Rikinari Hanayama, Tomoharu Yoshizumi, Masaki Mori, and Tatsuya Kanto.
   Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma Sci Rep. 2019 Oct 31;9(1):15788. doi: 10.1038/s41598-019-52356-6.
   
   
   
4. Yuzuru Sakamoto, Sachiyo Yoshio, Hiroyoshi Doi, Hironari Kawai, Tomonari Shimagaki, Taizo Mori, Michitaka Matsuda, Yoshihiko Aoki, Yosuke Osawa, Yuji Yoshida, Taeang Arai, Norio Itokawa, Takanori Ito, Yuya Seko, Kanji Yamaguchi, Yoshihito Itoh, Yoshihiro Mise, Akio Saiura, Akinobu Taketomi, Tatsuya Kanto
   Serum soluble Siglec-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease Hepatol Res. 2019 Dec 5. doi: 10.1111/hepr.13464.
   
   
   

共著論文

1. Komatsu H, Inui A, Kishiki K, Kawai H, Yoshio S, Osawa Y, Kanto T, Fujisawa T.
   Liver disease secondary to congenital heart disease in children. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):651-666. doi: 10.1080/17474124.2019.1621746. Epub 2019 May 26.
   
   
2. Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, Torimura T.
   High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2019 Sep;49(9):1046-1053. doi: 10.1111/hepr.13350. Epub 2019 May 29.